We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
As the call for the reimportation of prescription drugs grows louder on Capitol Hill and in state capitals, the nation’s second-largest drugmaker and the industry’s trade association are embarking on campaigns to change the tenor of the debate.
More than a week after receiving final FDA approval, generic firms Sandoz and Alphapharm have yet to launch their versions of GlaxoSmithKline’s (GSK’s) profitable antidepressant Paxil (paroxetine HCl).
Drugmakers with products in the lucrative antidepressant therapeutic class can expect to see their sales stall during the next decade as generic competition intensifies, according to a new study by Decision Resources.
In the latest move by a state to lower drug costs, West Virginia lawmakers overwhelmingly passed a bill Saturday that calls on the brand industry to establish a drug discount clearinghouse that could force companies to set their prices at lower rates established by federal or Canadian programs.
As the call for the reimportation of Rx drugs grows louder on Capitol Hill and in state capitals, the No. 2 drugmaker and the industry’s trade association are embarking on campaigns to change the tenor of the debate.
The Justice Department has launched a formal probe into Pfizer’s sales practices for two products that account for more than $1 billion in annual U.S. sales, the firm has announced in a regulatory filing.
A federal district court in Maine late Tuesday issued a preliminary injunction blocking a Maine law that would have designated pharmaceutical benefit managers (PBMs) as fiduciaries, requiring them to disclose proprietary pricing information negotiated with drugmakers.
States that look to drugs from Canada as a solution to lowering pharmaceutical expenses are overlooking existing means to reduce drug costs in their healthcare programs, including increased use of generics, FDA Commissioner Mark McClellan said Feb. 26.
The FTC is considering ways to ensure that brand firms do not apply a new legal delay tactic against generic competition that uses the fear of crippling financial damages to prevent generic products from coming to market.